Modus Therapeutics Holding AB
The answer first
Does Modus Therapeutics Holding beat the market?
No, Modus Therapeutics Holding has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 17% of Nordic stocks
- Quality91
- Value5
- Trend3
No. 143 of 195 in healthcare
Max for seven days
Follow Modus Therapeutics Holding with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Modus Therapeutics Holding
Your first answer is free, no account needed.
Do you own Modus Therapeutics Holding, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Modus Therapeutics Holding and a few more. Free, no card.
Super Stock+44.6%In short
- Modus Therapeutics Holding has fallen 61.2% over the past year, including dividends.
- Overall, Modus Therapeutics Holding ranks better than 17% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.0%. The price is 97.8% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 17% of Nordic stocks.
No. 143 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 33 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.49
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−171.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 167 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.0
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 186 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−60.0%
- 6 months−65.1%
- 9 months−52.4%
- 12 months−61.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Modus Therapeutics Holding
One fund we follow owns Modus Therapeutics Holding. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Modus Therapeutics Holding
Modus Therapeutics Holding AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.


See the full analysis of Modus Therapeutics Holding.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card